Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The FDA has approved Paratek Pharmaceuticals Inc's (NASDAQ:PRTK) supplemental marketing application for the oral-only dosing regimen of Nuzyra for Community-Acquired Bacterial Pneumonia (CABP).
- The approval of an oral-only dose regimen for NUZYRA represents a significant opportunity to treat patients in either the outpatient or primary care setting to potentially reduces/eliminates hospitalizations and the associated risk and costs from a hospital stay, the company said.
- The FDA approved Nuzyra in 2018 as an antibiotic with both once-daily oral and intravenous formulations to treat CABP and acute bacterial skin and skin structure infections.
- Price Action: PRTK shares are up 7.6% at $8.84 during the market session on the last check Tuesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!